Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer (NCT07313579) | Clinical Trial Compass
RecruitingNot Applicable
Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer
Ukraine200 participantsStarted 2025-12-01
Plain-language summary
The study investigates the outcomes of hyperthermic intraperitoneal chemoperfusion (HIPEC) in combination with curative-intent gastrectomy in resectable locally-advanced and limited-metastatic (low peritoneal cancer index) gastric cancer.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 18-80
✓. Hystologicaly proven gastric adenocarcinoma
✓. ECOG status 0-1
✓. Written consent to participate in the study
✓. Medically and technically operable gastric tumor
✓. Only T4a or T4b tumours with any peritoneal cytology status
✓. Cytologically positive peritoneal washings (cyt+) with any T and N criteria
✓. Adequate haemopoetic, renal and hepatic function (Hb \> 120, PLT \> 150\*10\^9/l, ALT \< 60, AST \<40, total bilirubin \< 21 µmol/l, Creatinine clearance (male - 90-140, female - 80-130 ml/min)
Exclusion criteria
✕. Pregnancy/breastfeeding
✕. ECOG status 2-4
✕. Concomitant malignancy
✕. Mitomycin and/or Cisplatin hypersensitivity
✕. Uncontrollable chronic diseases
✕. Patients with coexisting malignancy other than basal cell carcinoma of the skin within the last five years.
✕
What they're measuring
1
Peritoneal recurrence rate
Timeframe: From enrolment up to 5 years of follow-up